Investing

Sangamo Therapeutics : SGMO

SGMO

Stock Data

$0.14

$0.02 (13.26%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Sangamo Therapeutics Inc is at the forefront of genomic medicine, working to develop transformative treatments for serious diseases. With a focus on gene therapy, cell therapy, and genome editing, the company's pipeline includes potential therapies for Fabry disease, hemophilia A, sickle cell disease, and prevention of kidney transplant rejection. Based in Brisbane, California, Sangamo is collaborating with leading biopharmaceutical companies to advance its clinical trials and preclinical research, aiming to change the lives of patients and families affected by genetic diseases.

All Sangamo Therapeutics Articles

34 Articles

Lee Jackson | Feb 28, 2023 at 8:43 AM EST

Tuesday’s Top Analyst Upgrades and Downgrades: American Tower, Best Buy, Dominion Energy, Shell, Southwest Airlines, Union Pacific and More

Tuesday's top analyst upgrades and downgrades included American Tower, Best Buy, Dominion Energy, Intuit, NetEase, Shell, Southwest Airlines, State Street…

Chris Lange | Jun 13, 2022 at 10:59 AM EDT

From Bad to Even Worse: Analysts Upgrade or Downgrade Micron Technology, T. Rowe Price, Zendesk and More

Monday's additional top analyst upgrades and downgrades included BioMarin Pharmaceutical, Micron Technology, Quanta Services, Sangamo Therapeutics, Silvergate Capital, T. Rowe…

Jon C. Ogg | Jul 7, 2020 at 9:12 AM EDT

Top Analyst Upgrades and Downgrades: Ambarella, Annaly, Cinedigm, Fortinet, Kinder Morgan, 3M, Nikola, Nvidia, Tesla, Uber, YETI and More

Tuesday's top analyst upgrades and downgrades included Ambarella, Annaly Capital Management, Cinedigm, Fortinet, Kinder Morgan, 3M, Nikola, Nvidia, Tesla, Uber…

Jon C. Ogg | Feb 27, 2020 at 4:30 PM EST

Sangamo Partners With Biogen to Target Alzheimer’s and Parkinson’s Development

Many of the larger biotechnology and pharmaceutical companies have changed strategies from making acquisitions of speculative biotech outfits. In many…

Chris Lange | Jul 8, 2019 at 3:49 PM EDT

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated…

Chris Lange | Apr 2, 2019 at 11:40 AM EDT

What’s Next for Sangamo After This Hemophilia Study

Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with…

Jon C. Ogg | Mar 20, 2019 at 4:25 PM EDT

Why Pfizer Is Getting Deeper Into Gene Therapy

Gene therapy may become the next frontier for drug companies seeking to make billions of dollars improving or even curing…

Jon C. Ogg | Nov 14, 2018 at 9:05 AM EST

Top Analyst Upgrades and Downgrades: Alphabet, Amarin, Apple, AutoNation, BlackRock, E*Trade, Etsy, Kellogg, PG&E and More

The top analyst upgrades, downgrades and initiations seen on Wednesday included Alphabet, Amarin, Apple, AutoNation, BlackRock, E*Trade, Etsy, Kellogg and…

Jon C. Ogg | Nov 9, 2018 at 9:15 AM EST

Top Analyst Upgrades and Downgrades: ArcelorMittal, Barclays, Cree, Ctrip.com, Michael Kors, PVH, Skyworks, TripAdvisor, YRC Worldwide, Yelp and More

The top analyst upgrades, downgrades and initiations seen on Friday included ArcelorMittal, Barclays, Cree, Ctrip.com, Michael Kors, PVH, Skyworks Solutions,…

Jon C. Ogg | Feb 22, 2018 at 2:52 PM EST

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.

Chris Lange | Feb 22, 2018 at 10:20 AM EST

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into…

Chris Lange | Jan 3, 2018 at 10:45 AM EST

Sangamo Jumps on Newest Pfizer Collaboration

Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with…

Chris Lange | Dec 30, 2017 at 8:55 AM EST

30 Big Biotech Events Coming in 2018

Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock…

Chris Lange | Jul 1, 2017 at 9:00 AM EDT

The 11 Biggest and Best Analyst Upgrades of June

While some of the price targets discussed here call for a stock to double, or even to rise exponentially, it…

Chris Lange | Jun 22, 2017 at 9:30 AM EDT

Jefferies Sees 6 Biotechs as Undervalued With Massive Upside

Jefferies has picked out a few companies in the biotech industry that stand to win big over the coming year.